These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

140 related articles for article (PubMed ID: 39399157)

  • 1. Three-Year Overall Survival Outcomes and Correlative Analyses in Patients With NSCLC and High (50%-89%) Versus Very High (≥90%) Programmed Death-Ligand 1 Expression Treated With First-Line Pembrolizumab or Cemiplimab.
    Ricciuti B; Elkrief A; Lin J; Zhang J; Alessi JV; Lamberti G; Gandhi M; Di Federico A; Pecci F; Wang X; Makarem M; Murilo Hidalgo Filho C; Gorria T; Saini A; Pabon C; Lindsay J; Pfaff KL; Welsh EL; Nishino M; Sholl LM; Rodig S; Kilickap S; Rietschel P; McIntyre DA; Pouliot JF; Altan M; Gainor JF; Heymach JV; Schoenfeld AJ; Awad MM
    JTO Clin Res Rep; 2024 Sep; 5(9):100675. PubMed ID: 39399157
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Low peripheral blood derived neutrophil-to-lymphocyte ratio (dNLR) is associated with increased tumor T-cell infiltration and favorable outcomes to first-line pembrolizumab in non-small cell lung cancer.
    Alessi JV; Ricciuti B; Alden SL; Bertram AA; Lin JJ; Sakhi M; Nishino M; Vaz VR; Lindsay J; Turner MM; Pfaff K; Sharma B; Felt KD; Rodig SJ; Gainor JF; Awad MM
    J Immunother Cancer; 2021 Nov; 9(11):. PubMed ID: 34824161
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Programmed Death-Ligand 1 Tumor Proportion Score and Overall Survival From First-Line Pembrolizumab in Patients With Nonsquamous Versus Squamous NSCLC.
    Doroshow DB; Wei W; Gupta S; Zugazagoitia J; Robbins C; Adamson B; Rimm DL
    J Thorac Oncol; 2021 Dec; 16(12):2139-2143. PubMed ID: 34455068
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Pembrolizumab versus chemotherapy for previously untreated, PD-L1-expressing, locally advanced or metastatic non-small-cell lung cancer (KEYNOTE-042): a randomised, open-label, controlled, phase 3 trial.
    Mok TSK; Wu YL; Kudaba I; Kowalski DM; Cho BC; Turna HZ; Castro G; Srimuninnimit V; Laktionov KK; Bondarenko I; Kubota K; Lubiniecki GM; Zhang J; Kush D; Lopes G;
    Lancet; 2019 May; 393(10183):1819-1830. PubMed ID: 30955977
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Network meta-analysis of immune-oncology monotherapy as first-line treatment for advanced non-small-cell lung cancer in patients with PD-L1 expression ⩾50.
    Freemantle N; Xu Y; Wilson FR; Guyot P; Chen CI; Keeping S; Konidaris G; Chan K; Kuznik A; Atsou K; Glowienka E; Pouliot JF; Gullo G; Rietschel P
    Ther Adv Med Oncol; 2022; 14():17588359221105024. PubMed ID: 35747163
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Clinical outcomes in non-small cell lung cancer patients with an ultra-high expression of programmed death ligand-1 treated using pembrolizumab as a first-line therapy: A retrospective multicenter cohort study in Japan.
    Edahiro R; Kanazu M; Kurebe H; Mori M; Fujimoto D; Taniguchi Y; Suzuki H; Hirano K; Yokoyama T; Morita M; Fukuda Y; Uchida J; Makio T; Tamiya M
    PLoS One; 2019; 14(7):e0220570. PubMed ID: 31365588
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Pembrolizumab plus chemotherapy versus chemotherapy alone in patients with advanced non-small cell lung cancer without tumor PD-L1 expression: A pooled analysis of 3 randomized controlled trials.
    Borghaei H; Langer CJ; Paz-Ares L; Rodríguez-Abreu D; Halmos B; Garassino MC; Houghton B; Kurata T; Cheng Y; Lin J; Pietanza MC; Piperdi B; Gadgeel SM
    Cancer; 2020 Nov; 126(22):4867-4877. PubMed ID: 32914866
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Cost-effectiveness analysis of pembrolizumab versus chemotherapy as first-line treatment in locally advanced or metastatic non-small cell lung cancer with PD-L1 tumor proportion score 1% or greater.
    She L; Hu H; Liao M; Xia X; Shi Y; Yao L; Ding D; Zhu Y; Zeng S; Shen L; Huang J; Carbone DP
    Lung Cancer; 2019 Dec; 138():88-94. PubMed ID: 31655368
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Five Year Survival Update From KEYNOTE-010: Pembrolizumab Versus Docetaxel for Previously Treated, Programmed Death-Ligand 1-Positive Advanced NSCLC.
    Herbst RS; Garon EB; Kim DW; Cho BC; Gervais R; Perez-Gracia JL; Han JY; Majem M; Forster MD; Monnet I; Novello S; Gubens MA; Boyer M; Su WC; Samkari A; Jensen EH; Kobie J; Piperdi B; Baas P
    J Thorac Oncol; 2021 Oct; 16(10):1718-1732. PubMed ID: 34048946
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Safety and efficacy of pembrolizumab monotherapy in elderly patients with PD-L1-positive advanced non-small-cell lung cancer: Pooled analysis from the KEYNOTE-010, KEYNOTE-024, and KEYNOTE-042 studies.
    Nosaki K; Saka H; Hosomi Y; Baas P; de Castro G; Reck M; Wu YL; Brahmer JR; Felip E; Sawada T; Noguchi K; Han SR; Piperdi B; Kush DA; Lopes G
    Lung Cancer; 2019 Sep; 135():188-195. PubMed ID: 31446994
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Phase 1 Expansion Cohort of Ramucirumab Plus Pembrolizumab in Advanced Treatment-Naive NSCLC.
    Herbst RS; Arkenau HT; Bendell J; Arrowsmith E; Wermke M; Soriano A; Penel N; Santana-Davila R; Bischoff H; Chau I; Mi G; Wang H; Rasmussen E; Ferry D; Chao BH; Paz-Ares L
    J Thorac Oncol; 2021 Feb; 16(2):289-298. PubMed ID: 33068794
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Five-Year Outcomes With Pembrolizumab Versus Chemotherapy as First-Line Therapy in Patients With Non-Small-Cell Lung Cancer and Programmed Death Ligand-1 Tumor Proportion Score ≥ 1% in the KEYNOTE-042 Study.
    de Castro G; Kudaba I; Wu YL; Lopes G; Kowalski DM; Turna HZ; Caglevic C; Zhang L; Karaszewska B; Laktionov KK; Srimuninnimit V; Bondarenko I; Kubota K; Mukherjee R; Lin J; Souza F; Mok TSK; Cho BC
    J Clin Oncol; 2023 Apr; 41(11):1986-1991. PubMed ID: 36306479
    [No Abstract]   [Full Text] [Related]  

  • 13. Pembrolizumab as first-line therapy for patients with PD-L1-positive advanced non-small cell lung cancer: a phase 1 trial.
    Hui R; Garon EB; Goldman JW; Leighl NB; Hellmann MD; Patnaik A; Gandhi L; Eder JP; Ahn MJ; Horn L; Felip E; Carcereny E; Rangwala R; Lubiniecki GM; Zhang J; Emancipator K; Roach C; Rizvi NA
    Ann Oncol; 2017 Apr; 28(4):874-881. PubMed ID: 28168303
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Pembrolizumab vs cemiplimab for the treatment of advanced non-small cell lung cancer with PD-L1 expression levels of at least 50%: A network meta-analysis and cost-effectiveness analysis.
    Li Y; Liang X; Yang T; Guo S; Chen X
    Front Oncol; 2022; 12():878054. PubMed ID: 36226060
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Pembrolizumab Plus Chemotherapy for Metastatic NSCLC With Programmed Cell Death Ligand 1 Tumor Proportion Score Less Than 1%: Pooled Analysis of Outcomes After Five Years of Follow-Up.
    Gadgeel SM; Rodríguez-Abreu D; Halmos B; Garassino MC; Kurata T; Cheng Y; Jensen E; Shamoun M; Rajagopalan K; Paz-Ares L
    J Thorac Oncol; 2024 Aug; 19(8):1228-1241. PubMed ID: 38642841
    [TBL] [Abstract][Full Text] [Related]  

  • 16. First-Line Pembrolizumab Monotherapy for Advanced NSCLC With Programmed Death-Ligand 1 Expression Greater Than or Equal to 50%: Real-World Study Including Older Patients in Japan.
    Goto Y; Tamura A; Matsumoto H; Isobe K; Ozaki T; Santorelli ML; Taniguchi K; Kamitani T; Irisawa M; Kanda K; Abe M; Burke T; Nokihara H
    JTO Clin Res Rep; 2022 Sep; 3(9):100397. PubMed ID: 36065450
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Randomized clinical trial of pembrolizumab vs chemotherapy for previously untreated Chinese patients with PD-L1-positive locally advanced or metastatic non-small-cell lung cancer: KEYNOTE-042 China Study.
    Wu YL; Zhang L; Fan Y; Zhou J; Zhang L; Zhou Q; Li W; Hu C; Chen G; Zhang X; Zhou C; Dang T; Sadowski S; Kush DA; Zhou Y; Li B; Mok T
    Int J Cancer; 2021 May; 148(9):2313-2320. PubMed ID: 33231285
    [TBL] [Abstract][Full Text] [Related]  

  • 18. First-Line ICI Monotherapies for Advanced Non-small-cell Lung Cancer Patients With PD-L1 of at Least 50%: A Cost-Effectiveness Analysis.
    Liu Q; Zhou Z; Luo X; Yi L; Peng L; Wan X; Tan C; Zeng X
    Front Pharmacol; 2021; 12():788569. PubMed ID: 34992538
    [No Abstract]   [Full Text] [Related]  

  • 19. KEYNOTE-033: Randomized phase 3 study of pembrolizumab vs docetaxel in previously treated, PD-L1-positive, advanced NSCLC.
    Ren S; Feng J; Ma S; Chen H; Ma Z; Huang C; Zhang L; He J; Wang C; Zhou J; Danchaivijtr P; Wang CC; Vynnychenko I; Wang K; Orlandi F; Sriuranpong V; Li B; Ge J; Dang T; Zhou C
    Int J Cancer; 2023 Aug; 153(3):623-634. PubMed ID: 37141294
    [TBL] [Abstract][Full Text] [Related]  

  • 20. First-line cemiplimab monotherapy and continued cemiplimab beyond progression plus chemotherapy for advanced non-small-cell lung cancer with PD-L1 50% or more (EMPOWER-Lung 1): 35-month follow-up from a mutlicentre, open-label, randomised, phase 3 trial.
    Özgüroğlu M; Kilickap S; Sezer A; Gümüş M; Bondarenko I; Gogishvili M; Nechaeva M; Schenker M; Cicin I; Ho GF; Kulyaba Y; Zyuhal K; Scheusan RI; Garassino MC; He X; Kaul M; Okoye E; Li Y; Li S; Pouliot JF; Seebach F; Lowy I; Gullo G; Rietschel P
    Lancet Oncol; 2023 Sep; 24(9):989-1001. PubMed ID: 37591293
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.